TruAlt Bioenergy Ltd. (TRUALT) — Tipsheet

TruAlt Bioenergy lands ₹150 cr government grant for SAF plant

Tipsheet Editorial — Thu, 18 Jun 2026 18:00:23 GMT

The grant under PM JI-VAN Yojana covers 7-10% of project capex, boosting India's 1% SAF blending target by 2027 and validating TruAlt's strategic direction.

What’s new

₹150 cr government assistance for Bagalkot SAF facility approved under PM JI-VAN Yojana
Grant covers 7-10% of project capex, improving financial viability
Facility targets 10 crore litres annual SAF capacity; supports 1% blend by 2027 mandate

Why it matters

For a small-cap with declining revenues and a debt-to-equity of 2.02, this government backing reduces execution risk and signals policy support. It partly reverses the negative narrative from the earlier project pushback.

What we’re watching

Timely execution of the Bagalkot facility—capex and commissioning schedule
Ethanol sales recovery to improve cash flows amid weak profit trends
Global SAF demand under CORSIA and India's blend mandate progression

The full read

TruAlt Bioenergy just secured the government's stamp on its SAF ambitions. The ₹150 crore grant under PM JI-VAN Yojana covers 7-10% of the planned Bagalkot facility's capital expenditure, a genuine de-risking move for a small-cap with a debt-to-equity of 2.02 and declining revenues. The facility targets 10 crore litres of sustainable aviation fuel annually, enough to feed India's 1% blending mandate by 2027. This endorsement matters more than the quantum: it comes after TruAlt pushed back its SAF timeline in late May and reported a 45% drop in FY26 net profit. Government backing doesn't erase execution risk, but it changes the conversation. For a company that was losing credibility, this grant rebuilds some. The next test is building the plant.

Primary source: BSE · NSE

TruAlt Bioenergy pushes back SAF project as ethanol volumes miss targets

Tipsheet Editorial — Fri, 22 May 2026 18:44:59 GMT

The company missed ethanol sales by 35% amid an allocation dispute with oil marketers, while its sustainable aviation fuel project now faces a two-year delay.

What’s new

Oil Marketing Companies allocated 26 crore liters of ethanol, against TruAlt's 72-crore bid.
Sustainable aviation fuel (SAF) commissioning delayed from August 2027 to FY29.
Joint ventures with Sumitomo and GAIL aim for 162 tonnes per day of biogas capacity by Q4 FY27.

Why it matters

The company’s growth narrative hinges on diversifying from ethanol into SAF and biogas. A delay in the SAF project, coupled with persistent friction over ethanol allocations, suggests that scaling these new lines will take longer than investors had been led to expect.

What we’re watching

Implementation status of the 15-crore-liter court order for ethanol supply.
Progress on securing long-term offtake agreements for the SAF project.
Capacity ramp-up milestones for the new compressed biogas plants.

The full read

TruAlt Bioenergy’s ethanol business is running into structural headwinds. Management confirmed on May 22 that fiscal 2026 sales volume finished 35% below their internal target, pinned on Oil Marketing Companies granting only 26 crore liters against the company's 72-crore bid. A 15-crore-liter supply gap remains stuck in legal proceedings. Beyond the current core, the company is recalibrating its future: the sustainable aviation fuel (SAF) project has slipped from an August 2027 target to FY29. Management cited the need for firm long-term offtake agreements before committing capital to a final investment decision. In the interim, TruAlt is betting on compressed biogas (CBG) expansion via joint ventures with Sumitomo and GAIL. That business is slated to hit 162 tonnes per day by Q4 FY27. What changes from here is the visibility of that SAF revenue, which now sits behind a multi-year delay and a requirement for new contracts.

Primary source: BSE · NSE

TruAlt Bioenergy's profit halves as revenue drops; no new catalysts in filing

Tipsheet Editorial — Fri, 22 May 2026 17:31:32 GMT

Standalone net profit fell from ₹14,862 lakhs to ₹8,983 lakhs in FY26. The audited results confirm a known downtrend without new drivers.

What’s new

FY26 standalone net profit dropped to ₹8,983 lakhs from ₹14,862 lakhs; EPS halved to ₹10.23.
The consolidated financials also show a decline in both revenue and profit versus the prior year.
No new strategic updates; previously disclosed partnerships and the Karnataka ethanol order were reiterated.

Why it matters

The filing is a routine but material disclosure of a sharp earnings decline. It adds no new catalysts to a story the market already knows, confirming a deteriorating financial trajectory without a clear near-term reversal plan.

What we’re watching

Whether the previously announced Karnataka ethanol and CBG deals generate meaningful FY27 revenue.
The timeline for resolving the auditor's emphasis on pending asset componentisation.
Next quarter's results for any sign of margin stabilization.

The full read

TruAlt Bioenergy's FY26 audited results confirm a sharp downturn. Standalone net profit fell to ₹8,983 lakhs from ₹14,862 lakhs, with EPS halving to ₹10.23. The consolidated financials show a similar decline. The strategic partnerships driving future growth were all disclosed previously. This filing adds no new catalysts. The auditor's report is unmodified but flags pending asset componentisation. The core issue is the gap between the company's prior profitability and its current results. Closing it depends on converting announced deals into booked revenue. Not yet.

Primary source: BSE · NSE

TruAlt Bioenergy FY26 profits drop to ₹8,983 lakhs

Tipsheet Editorial — Fri, 22 May 2026 17:05:36 GMT

Standalone revenue fell 9% as earnings per share halved to ₹10.23.

What’s new

Standalone revenue fell to ₹1,70,405 lakhs from ₹1,88,012 lakhs.
Earnings per share dropped to ₹10.23, down from ₹20.08 last year.
The board re-confirmed stakes held by GAIL and Sumitomo Corp.

Why it matters

The company's core profitability is shrinking rapidly. Strategic partnerships exist, but they have yet to arrest the slide in earnings.

What we’re watching

Ethanol supply contract performance under the 90-day extension.
The impact of the Honeywell SAF technology deal on FY27 margins.
Whether the company stabilizes operating costs next quarter.

The full read

TruAlt Bioenergy ended FY2026 with a sharp reversal in financial health. Standalone revenue contracted to ₹1,70,405 lakhs from the prior year's ₹1,88,012 lakhs. Net profit took a harder hit, dropping to ₹8,983 lakhs from ₹14,862 lakhs. Shareholders saw earnings per share nearly halve to ₹10.23. The filing repeated details on external stakes held by GAIL and Sumitomo Corporation, alongside a Honeywell SAF technology deal. It also noted a 90-day extension for an ethanol supply contract worth ₹1,675 crore. These items were already known. They offer no cover for the current bottom-line erosion. The auditor report arrived with no modifications. The performance is weak. The firm now needs to prove it can turn its technology and supply-side agreements into actual margins before the next cycle hits.

Primary source: BSE · NSE